MEI Pharma Announces CMO Departure, Director Changes
Ticker: LITS · Form: 8-K · Filed: Mar 7, 2025 · CIK: 1262104
| Field | Detail |
|---|---|
| Company | Mei Pharma, INC. (LITS) |
| Form Type | 8-K |
| Filed Date | Mar 7, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: executive-departure, board-changes, compensation
TL;DR
MEI Pharma's CMO is out, new directors in, and comp plans are changing.
AI Summary
MEI Pharma, Inc. announced on March 3, 2025, the departure of Dr. Brian D. D. Smith from his role as Chief Medical Officer. The company also reported on the election of new directors and changes in officer compensation arrangements.
Why It Matters
Changes in key executive positions and board composition can signal shifts in company strategy or operational focus.
Risk Assessment
Risk Level: medium — Executive departures and changes in compensation can indicate internal challenges or strategic realignments that may impact future performance.
Key Players & Entities
- MEI Pharma, Inc. (company) — Registrant
- Dr. Brian D. D. Smith (person) — Departing Chief Medical Officer
- March 03, 2025 (date) — Date of earliest event reported
FAQ
Who has departed from MEI Pharma, Inc.?
Dr. Brian D. D. Smith has departed from his role as Chief Medical Officer.
What is the date of the earliest event reported in this filing?
The date of the earliest event reported is March 03, 2025.
What are the main items covered in this 8-K filing?
This filing covers the departure of certain officers, election of directors, and compensatory arrangements of certain officers, as well as financial statements and exhibits.
In which state is MEI Pharma, Inc. incorporated?
MEI Pharma, Inc. is incorporated in Delaware.
What is the principal executive office address for MEI Pharma, Inc.?
The principal executive office is located at 9920 Pacific Heights Blvd., Suite 150, San Diego, California, 92121.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on March 7, 2025 by Dr. Brian D. D. Smith regarding MEI Pharma, Inc. (LITS).